Smartleaf Asset Management
NKTR icon

Smartleaf Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Smartleaf Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$118 Hold
2
– – ﹤0.01% 3535
2026
Q2 		$131 Hold
2
– – ﹤0.01% 3347
2026
Q1 		$130 Hold
2
– – ﹤0.01% 3380
2025
Q4 		$84 Buy
+2
New +$112 ﹤0.01% 3409
2024
Q4 		– Sell
-19
Closed -$329 – 2984
2024
Q3 		$329 Buy
+19
New +$362 ﹤0.01% 2835

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
Creek Drive Management Group
Creek Drive Management Group San Francisco, California $368M AUM 23.05% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Emerald Mutual Fund Advisers Trust
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return
Quinn Opportunity Partners
Quinn Opportunity Partners Charlottesville, Virginia $1.85B AUM 1.27% 1-Year Est. Return

Smartleaf Asset Management's NKTR Position: Q3 2026 in Review

Smartleaf Asset Management held its Nektar Therapeutics (NKTR) position steady in Q3 2026 at 2 shares worth $118. The position accounts for ﹤0.01% of the portfolio, ranked #3535.

Smartleaf Asset Management first reported a position in NKTR in Q3 2024 and has held it in 5 quarters since. The position peaked at $329 in Q3 2024. 96 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.

  • Smartleaf Asset Management held 2 shares of Nektar Therapeutics worth $118 as of Q3 2026.
  • Smartleaf Asset Management left its Nektar Therapeutics share count unchanged in Q3 2026.
  • Nektar Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q3 2026, its #3535 holding.
  • Smartleaf Asset Management first reported a position in Nektar Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • Smartleaf Asset Management's Nektar Therapeutics position peaked at $329 in Q3 2024.
  • 96 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.

Based on Smartleaf Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.